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Summary:  
Genes whose function is selectively essential in the presence of cancer 
associated genetic aberrations represent promising targets for the 
development of precision therapeutics. Here we present CancerGD 
(www.cancergd.org), a resource that integrates genotypic profiling with large-
scale loss-of-function genetic screens in tumor cell lines to identify such 
genetic dependencies. CancerGD provides tools for searching, visualizing, 
and interpreting these genetic dependencies through the integration of 
functional interaction networks.  
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Highlights: 
 
• Integrating loss of function screens with sequencing identifies genetic 
dependencies 
• CancerGD facilitates searching and visualizing dependencies from 
multiple sources 
• CancerGD aids the interpretation of dependencies by integrating 
interaction networks 
 
Main Text: 
The ability to inhibit tumors in molecularly defined cohorts of patients is a 
cornerstone of precision cancer treatment. A successful approach has been 
the development of drugs that inhibit proteins specifically required in tumors 
harboring aberrations in recurrently altered cancer ‘driver genes’ (Luo et al., 
2009). For example, oncogene addiction effects, such as the increased 
sensitivity of ERBB2 (HER2) amplified breast tumors to ERBB2 inhibitors 
(Hynes and Lane, 2005), can be clinically exploited, as can non-oncogene 
addiction effects, such as the synthetic lethal relationship between 
BRCA1/BRCA2 mutations and PARP inhibitors (Lord et al., 2015). To identify 
additional cancer genetic dependencies (CGDs) that may ultimately be 
exploited therapeutically, multiple groups have performed large-scale loss-of-
function genetic screens in panels of tumor cell lines (Brough et al., 2011b; 
Campbell et al., 2016; Cheung et al., 2011; Cowley et al., 2014; Marcotte et 
al., 2012; Marcotte et al., 2016; Wang et al., 2017). Integrating the results of 
these screens with molecular profiling data creates hypothesis-generating 
resources where the hypotheses are of the form ‘tumor cells with a mutation 
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in gene X are sensitive to inhibition to of gene Y’. These hypotheses are 
typically tested in subsequent experiments – for example, in larger panels of 
cell lines, using orthogonal mechanisms of gene inhibition, and/or in mouse 
models – to ensure they are not statistical or experimental artefacts. Recent 
examples of novel CGDs discovered through genetic screening approaches 
include an increased sensitivity of ARID1A mutant cell lines to inhibition of the 
ARID1A paralog ARID1B (Helming et al., 2014), of PTEN mutant breast tumor 
cell lines to inhibition of the mitotic checkpoint kinase TTK (Brough et al., 
2011b), and of MYC amplified breast tumor cell lines to inhibition of multiple 
distinct splicing components (Hsu et al., 2015).  
 
Although the results of loss-of-function screens are typically made publically 
available, their integration with genotypic data remains challenging for those 
without bioinformatics skills. Sequencing and copy number data must be 
processed to identify likely functional alterations, cell line names matched 
between different data sources, and statistical analysis performed to identify 
associations between the alteration of driver genes and an increased 
sensitivity to inhibition of target genes. To address these challenges we have 
developed CancerGD (www.cancergd.org), a resource that integrates multiple 
loss-of-function screens (Campbell et al., 2016; Cowley et al., 2014; Marcotte 
et al., 2012; Marcotte et al., 2016; Wang et al., 2017) with genotype data 
(Forbes et al., 2015; Iorio et al., 2016; Yang et al., 2013) to identify CGDs 
associated with a panel of cancer driver genes (Figure 1).  
 
	 4	
CancerGD currently facilitates the searching, visualization, and interpretation 
of CGDs (Figure 1) associated with 53 driver genes (Table S1). These genes 
were selected based on their identification as driver genes in multiple 
independent analyses (Campbell et al., 2016; Forbes et al., 2015; Vogelstein 
et al., 2013) and due to their alteration in at least three tumor cell lines 
featured in one or more of the included loss-of-function screens. Driver gene 
associated CGDs are identified both across cell lines from multiple histologies 
(‘Pan Cancer’) and within tumor cell lines arising from specific primary sites 
(e.g. ‘Breast’). With an intuitive search interface it is thus possible to retrieve 
CGDs associated with ERBB2 amplification across cell lines from all tissue 
types or specifically associated with ERBB2 amplification in breast tumor 
models (Figure 2A). The data supporting every CGD can be visualized in an 
interactive box plot (Figure 2B) and downloaded for reference.  
 
Aside from oncogene addiction effects (Luo et al., 2009), which represent a 
tiny minority of the dependencies stored in CancerGD, the mechanistic 
interpretation of CGDs remains challenging. Why would mutation of one gene 
result in an increased dependency upon another? In yeast, the interpretation 
of such relationships has been greatly aided by the integration of protein-
protein interaction networks with genetic screens (Kelley and Ideker, 2005). 
Following a similar model, to aid the interpretation of CGDs in CancerGD we 
integrate functional interactions from the STRING database (Szklarczyk et al., 
2015). This facilitates the rapid identification of CGDs involving gene pairs 
with known functional relationships. For instance in the Campbell et al dataset 
(Campbell et al., 2016) ERBB2 amplification is associated with an increased 
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dependency upon the ERBB2 protein interaction partners JAK2 and ERBB3, 
as well as the ERBB2 downstream effector PIK3CA (Figure 2A). Similarly in 
the Cowley et al dataset (Cowley et al., 2014) loss or mutation of the BAF 
complex subunit ARID1A is associated with an increased dependency upon 
the ARID1A paralog and BAF complex member ARID1B (Helming et al., 
2014). Such dependencies may make more promising candidates for follow 
on experiments as they are supported by existing functional relationships in 
addition to the genetic association.  
 
In addition to identifying known functional interactions between the driver 
gene and associated dependency, it can be helpful to understand the 
relationships between all of the CGDs associated with a given driver gene.  
For instance we previously found that cell lines with a deletion or mutation of 
the tumor suppressor SMAD4 display a strong dependency upon the mitotic 
checkpoint kinase CHEK1 (Campbell et al., 2016). Considered in isolation it is 
not clear whether this CGD relates to a specific function of CHEK1 or a more 
general sensitivity to inhibition of the mitotic checkpoint. However, by 
analysing all of the dependencies associated with SMAD4 we found that they 
were densely connected on the protein interaction network and primarily 
involved in the mitotic checkpoint (Campbell et al., 2016), suggesting a more 
general sensitivity to perturbation of this pathway. To facilitate the 
identification of such pathway-level dependencies CancerGD provides 
network visualizations of the functional interactions between CGDs associated 
with each driver gene (Figure S1).  
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In contrast to the results of drug screening efforts in panels of tumor cell lines 
(Barretina et al., 2012; Basu et al., 2013; Daemen et al., 2013; Garnett et al., 
2012; Iorio et al., 2016; Yang et al., 2013), the CGDs identified in loss-of-
function screens include targets that have no inhibitors available and 
consequently may serve as the rationale for the development of new small-
molecule inhibitors. To facilitate the identification of CGDs that may be more 
readily exploited with available inhibitors CancerGD integrates drug-gene 
interaction relationships from DGIdb (Griffith et al., 2013). 
 
It has previously been highlighted that many CGDs identified in one loss-of-
function screen are not evident in additional datasets (Brough et al., 2011a; 
Downward, 2015). This could indicate that these CGDs are context specific 
(Lord et al., 2015) but can also be explained by a variety of technical factors. 
Different screens feature different coverage of gene libraries (e.g. kinome vs 
genome-wide), different coverage of cancer types (e.g. only melanoma in one 
vs only breast in another) and different coverage of driver genes (e.g. many 
BRAF mutant cell lines in one screen vs none in another). These technical 
factors can result in the identification of CGDs in one screen that cannot be 
observed in a second screen. Furthermore in any given screen there may be 
false positives resulting from the off-target effects of gene targeting reagents 
(Jackson and Linsley, 2010) and false negatives resulting from variation in the 
knockdown efficiencies of different gene targeting reagents (Kaelin, 2012). 
There are thus a number of explanations for why a CGD observed in one 
dataset may not be evident in another. Nonetheless, the CGDs that are 
observed in multiple datasets may be of particular interest as they are 
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perhaps less likely to result from the off-target effects of gene targeting 
reagents and also less likely to be highly context-specific. In CancerGD we 
provide functionality to identify and filter those CGDs observed independently 
in multiple datasets.  
 
CancerGD can incorporate datasets generated using different experimental 
and computational pipelines and is not restricted to loss-of-function screens 
generated using any specific method (shRNA / siRNA / CRISPR). The main 
requirement for inclusion is that a dataset must contain the results of screens 
in a panel of cell lines (a minimum of ten cell lines) and provide some 
quantitative measurement of the sensitivity of each cell line to the inhibition of 
each gene screened. Currently the resource includes three genome-scale 
shRNA screens (Cowley et al., 2014; Marcotte et al., 2012; Marcotte et al., 
2016), one kinome-wide siRNA screen (Campbell et al., 2016), and one 
genome-wide CRISPR screen (Wang et al., 2017). As additional screens 
become available we will incorporate their results into the resource (see 
methods for instructions on how to format screens for easy inclusion in 
CancerGD).  
 
A tutorial demonstrating the full functionality of CancerGD is provided in 
Document S1. We believe that CancerGD will be a useful resource to aid a 
wider group of cancer researchers to benefit from the information generated in 
large-scale loss-of-function screens.  
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Figure 1. CancerGD overview  
Loss-of-function screens from multiple sources are integrated with exome and 
copy number profiles from the GDSC resource. Cell lines are annotated 
according to the mutational status of a panel of driver genes. Statistical 
analysis is then performed to identify associations between the presence of 
driver gene alterations and sensitivity to reagents targeting specific genes. 
These CGDs are filtered such that only those with nominal significance 
(p<0.05) and moderate common language effect sizes (≥ 65%) are retained.  
Finally all CGDs are annotated according to whether they occur between 
driver-target pairs with known functional relationships (STRING) and whether 
there is an inhibitor available for the target gene (DGIdb).  
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Figure 2 
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Figure 2. Genetic dependency exploration and visualization 
A) The principle view of the database. Each row represents a gene identified 
as a dependency associated with ERBB2 amplification in Campbell et al 
(Campbell et al., 2016) across all tumor types (Pan cancer). Columns display 
experimental details along with the p-value, common language effect size and 
difference in median sensitivity score for each dependency. Genes identified 
as dependencies in multiple datasets are indicated in the ‘Multiple Hit’ column. 
Genes with a known functional relationship to the driver gene (e.g. PIK3CA) 
are indicated in the ‘String interaction’ column and drugs known to inhibit the 
target gene indicated in the ‘Inhibitors’ column. Toggles/search boxes permit 
easy filtering of interactions – e.g. to select only those genes with an 
associated inhibitor available. 
B) Example boxplot showing an increased sensitivity of ERBB2 amplified cell 
lines to inhibition of MAP2K3. Each data point represents the sensitivity of a 
particular cell line to RNAi reagents targeting MAP2K3. Cell lines are grouped 
according to ERBB2 amplification status with the wild-type group on the left 
and amplified group on the right. Cell lines are coloured according to site of 
origin and toggles on the right permit the hiding/showing of cell lines from 
specific sites. Hovering over a given data point provides the cell line’s name, 
the primary site, and the score associated with the RNAi reagent in that cell 
line. An overlapped box-whisker plot displays the interquartile range and the 
median for each group. High-resolution PNG images for each box plot can be 
downloaded along with a CSV file containing all of the data presented in the 
box plot. Links to the target gene (MAP2K3) on additional sites are provided 
at the bottom of the plot. 
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Figure S1 
 
 
 
Figure S1. Visualizing the known interactions between all CGDs 
associated with a specific driver gene. Related to Figure 2. 
 
High confidence STRING functional interactions between CGDs associated 
with ERBB2 amplification in Campbell et al are shown. 
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Table S1 
Gene Studies Tissues CGDS 
ACVR2A	 1	 2	 676	
AFDN	 1	 1	 396	
AFF4	 1	 1	 268	
APC	 1	 2	 905	
ARID1A	 4	 5	 2336	
ARID1B	 2	 2	 273	
ASXL1	 2	 2	 1648	
B2M	 1	 1	 294	
BCOR	 1	 2	 389	
BRAF	 1	 2	 562	
BRCA1	 1	 1	 798	
BRCA2	 2	 3	 1685	
CCND1	 3	 3	 1264	
CCNE1	 1	 1	 930	
CDH1	 3	 2	 1761	
CDKN2A	 5	 8	 4074	
CDKN2C	 1	 3	 1148	
CTNNB1	 1	 2	 455	
EGFR	 2	 2	 460	
EP300	 2	 3	 1698	
ERBB2	 4	 3	 2523	
EZH2	 1	 1	 587	
FANCA	 1	 2	 707	
FBXW7	 1	 2	 440	
GNAS	 2	 3	 1434	
HEY1	 1	 1	 643	
KDM6A	 1	 3	 743	
KRAS	 3	 4	 2205	
MAP2K4	 2	 2	 1048	
MDM2	 1	 1	 224	
MSH2	 1	 1	 172	
MSH6	 1	 2	 651	
MYC	 3	 5	 1782	
NCOA3	 1	 1	 931	
NCOR1	 1	 2	 540	
NF1	 3	 4	 1271	
NRAS	 2	 2	 1232	
PIK3CA	 4	 5	 2800	
PIK3R1	 1	 2	 372	
PPM1D	 3	 1	 1156	
PTCH1	 1	 1	 197	
PTEN	 4	 4	 2176	
PTPRK	 1	 1	 289	
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RB1	 3	 3	 1602	
RNF43	 2	 3	 1787	
RPL22	 1	 2	 836	
SKP2	 1	 1	 1095	
SMAD4	 3	 4	 1863	
SMARCA4	 2	 2	 437	
SPOP	 1	 1	 738	
STK11	 2	 2	 341	
TP53	 5	 9	 3690	
UBR5	 1	 2	 677	
 
Table S1. Driver genes currently included in CancerGD. Related to 
Figure 1 
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STAR Methods 
 
 
CONTACT FOR REAGENT AND RESOURCE SHARING  
 
Further information and requests for resources and reagents should be 
directed to and will be fulfilled by the Lead Contact, Colm J. Ryan 
(colm.ryan@ucd.ie) 
 
METHOD DETAILS 
Genotype data 
Exome data for ~1,000 cell lines are obtained from the GDSC resource (Iorio 
et al., 2016; Yang et al., 2013). We use this data to annotate ~500 driver 
genes (Campbell et al., 2016) according to whether they feature likely 
functional alterations.  For oncogenes we consider recurrent missense or 
recurrent in frame deletions/insertions to be likely functional alterations, where 
recurrence is defined as at least 3 previous mutations of a particular site in the 
COSMIC database (Forbes et al., 2015). In addition to recurrent missense or 
indel events, for tumor suppressors we consider that all nonsense, frameshift 
and splice-site mutations are likely functional alterations. For copy number 
analysis we use the gene level copy number scores from COSMIC for the 
same set of cell lines (which are derived from PICNIC analysis of Affymetrix 
SNP6.0 array data) (Forbes et al., 2015; Garnett et al., 2012; Iorio et al., 
2016; Yang et al., 2013). An oncogene is considered amplified if the entire 
coding sequence has 8 or more copies while a tumor suppressor is 
considered deleted if any part of the coding sequence has a copy number of 0 
as per Garnett et al (Garnett et al., 2012). For the majority of driver genes we 
integrate the two sources together. For all tumor suppressors we consider a 
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functional alteration to be either a deletion (derived from copy number 
profiles) or a presumed loss-of-function mutation (as identified in the exome 
data). For most oncogenes we consider a functional alteration to be either an 
amplification or a recurrent mutation/indel. For a small number of oncogenes 
(ERBB2, MYC, MYCN) we consider only amplifications as functional events, 
while for another group (KRAS, BRAF, NRAS, HRAS) we only consider 
recurrent mutations/indels.   
 
Loss of function screens 
Four large-scale RNAi datasets and one CRISPR dataset are currently 
included in CancerGD (Campbell et al., 2016; Cowley et al., 2014; Marcotte et 
al., 2012; Marcotte et al., 2016; Wang et al., 2017). These include a kinome 
focussed siRNA screen covering a panel of 117 cell lines from diverse 
histologies (Campbell et al., 2016), a genome-scale shRNA screen focussed 
on 77 breast tumor cell lines (Marcotte et al., 2016), a genome-scale shRNA 
screen focussed on 72 breast, ovarian and pancreatic cell lines(Marcotte et 
al., 2012), a large-scale shRNA screen covering 216 cell lines from diverse 
histologies (Cowley et al., 2014), and a genome-scale CRISPR screen 
covering 14 AML cell lines(Wang et al., 2017). Cowley et al (Cowley et al., 
2014) is largely a superset of a previous screen from the same lab (Cheung et 
al., 2011) and hence the two resources are not included separately. Similarly 
the kinome siRNA screen from Cambell et al (Campbell et al., 2016) contains 
the majority of the breast tumor cell lines screened in a previous breast 
cancer kinome siRNA screen from the same lab (Brough et al., 2011b) and 
hence they are not included separately. The breast cell lines in (Marcotte et 
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al., 2016) are a superset of those included in (Marcotte et al., 2012) and 
consequently we do not store breast specific dependencies from (Marcotte et 
al., 2012). 
 
Cell line naming  
Internally we follow the naming convention established by the Cancer Cell 
Line Encyclopedia (Barretina et al., 2012). The CCLE naming convention is 
the cell line name (containing only numbers and upper case letters) followed 
by an underscore, followed by the tissue/primary site in upper case. The cell 
line names are taken from (Iorio et al., 2016), converted to uppercase and 
punctuation removed. Where possible we use the same tissue types as the 
CCLE, in a small number of cases where a tissue was absent from the CCLE 
(e.g. CERVIX) we have created a new tissue type. Having the tissue type in 
the cell line name facilitates filtering the boxplots (e.g. to show the gene 
inhibition sensitivities for cell lines from a specific tissue) in the browser 
without having to perform additional database queries. Furthermore two of the 
published loss-of-function screens already follow this naming convention 
(Campbell et al., 2016; Cowley et al., 2014) while a third features only breast 
cell lines and was trivially converted (Marcotte et al., 2016). In instances 
where the same cell line is featured in two datasets but there is a naming 
disagreement (e.g. H1299_LUNG in Campbell et al (Campbell et al., 2016) is 
NCIH1299_LUNG in our genotype set) we manually rename the screen 
dataset to match the genotype data. 
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Gene identification 
CancerGD provides links to multiple external sources that use a variety of 
different gene identifiers. Consequently for each gene in the database we 
store multiple identifiers (Entrez Gene ID, Ensembl Gene identifiers, HUGO 
Gene Names, Ensembl Protein IDs). We also store synonyms for each gene 
to facilitate easy gene look up (e.g. ERBB2 can be identified by searching for 
HER2). These synonyms are obtained from the HGNC resource (Gray et al., 
2015). 
 
Drug target annotations 
Drug-gene relationships are obtained from the Drug-Gene Interaction 
Database (DGIdb), which integrates drug-gene relationships from multiple 
sources (Wagner et al., 2016). Only inhibitor relationships are retrieved, as we 
are interested in drugs that inhibit the products of specific genes, rather than 
drugs whose efficacy is associated with the mutation of specific genes. 
Results from DGIdb sourced from MyCancerGenome and 
MyCancerGenomeClinicalTrial are excluded for the same reason.  
 
Functional interactions 
Functional interactions are obtained from STRING. We store all interactions 
that are medium confidence (STRING score > 0.4) or higher. Cut-offs to 
identify interactions as ‘Medium’, ‘High’ and ‘Highest’ confidence are those 
defined by STRING. For displaying the functional interactions between the 
dependencies associated with each driver gene we use the STRING API 
(Szklarczyk et al., 2015). 
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Implementation 
CancerGD is implemented in Python using the Django framework and follows 
a model/view/controller architecture. JQuery is used for Javascript processing 
in the browser interface.  MySQL is used by default for data storage but 
SQLite can be used for development / testing purposes with minimal 
documented changes. The application is currently hosted on the 
PythonAnywhere system, a generic Python web services host, suggesting 
that the application is portable.  
 
Formatting screens for CancerGD 
To enable easy inclusion of future screens in CancerGD we request that data 
be provided as a tab-delimited table with each row representing a particular 
cell line and each column representing reagents targeting a specific gene. 
Cell line names should preferably follow the Cancer Cell Line Encyclopaedia 
naming convention described above, but COSMIC IDs are also acceptable. 
Genes should preferably be identified using ENTREZ IDs but other unique IDs 
(ENSEMBL Gene IDs) are acceptable. Due to regular changing and updating, 
gene symbols alone should not be used as unique gene identifiers. We favour 
SYMBOL_ENTREZID (e.g KRAS_3846) for ease of use but this is not 
required. In cases where multiple distinct scores are provided for a specific 
gene, as happens with scores from the ATARIS algorithm, we request that 
they be identified using distinct suffixes (e.g. KRAS_3846_1, KRAS_3846_2). 
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Individual entries in the table should be quantitative scores indicating how 
sensitive a specific cell line is to perturbation of a particular gene. As different 
scoring procedures are used to quantify the results of screens using different 
experimental approaches (e.g. ATARIS (Shao et al., 2013) and zGARP 
(Marcotte et al., 2012) for shRNA screens, Z-score for siRNA screens 
(Campbell et al., 2016)) we do not require the scores to be in any standard 
format or range. However, we follow the convention in the field and suggest 
that increasingly negative scores should indicate greater inhibition of cell 
growth. A sample screen from Campbell et al (Campbell et al., 2016) is 
provided in the appropriate format here: 
http://www.cancergd.org/static/gendep/Campbell_cancergd.txt 
  
QUANTIFICATION AND STATISTICAL ANALYSIS 
We use R for all statistical analysis. For each driver gene / target gene 
combination we compare cell lines harbouring a likely functional alteration in 
the driver gene to cell lines with no alteration in that gene and test if the cell 
lines with the functional alteration are more sensitive to RNAi reagents that 
inhibit that gene. This is tested using a one-sided Mann-Whitney U test. A 
variety of alternative two-sample tests have been used in previous 
publications, including median permutation tests (Brough et al., 2011b; 
Campbell et al., 2016) and mutual information based measures (Cowley et al., 
2014). The Mann-Whitney U test has a number of advantages for CancerGD 
– it is rapid to calculate and it does not assume that the scores for each gene 
are normally distributed. The latter is important as it means the test can be 
used uniformly on loss-of-function screens from multiple sources that use 
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different scoring schemes. For all screens we use the authors’ provided 
scoring scheme (zGARP for Marcotte et al (Marcotte et al., 2012; Marcotte et 
al., 2016), ATARIS phenotype score for Cowley et al (Cowley et al., 2014), 
robust Z-score for Campbell et al (Campbell et al., 2016), and CS score for 
Wang et al (Wang et al., 2017)). As in (Marcotte et al., 2012) we apply Z-
score normalization to the zGARP scores from (Marcotte et al., 2012) to 
enable reasonable comparison of scores across cell lines. In addition to the p-
value from the Mann-Whitney U test we calculate a common language effect 
size (CLES) for each dependency. The CLES is equivalent to the Area under 
the ROC curve and the Probability of Superiority and indicates the probability 
that a cell line with an alteration in a particular driver gene is more sensitive to 
a given RNAi reagent than a cell line without that alteration. In the database 
we store all nominally significant dependencies (p<0.05) with a CLES ≥ 0.65. 
In a small number of instances multiple ATARIS scores are presented for a 
single gene – when storing CGDs we incorporate the ATARIS score with the 
lower p-value. 
 
DATA AND SOFTWARE AVAILABILITY 
Source code for the entire project (R/Python/Javascript/HTML) is publicly 
available on GitHub (https://github.com/cancergenetics/cancergd). Detailed 
instructions on how to run the statistical analysis, install the web application 
and populate the database are also provided in the GitHub repository 
(CancerGD_Manual_v1.1.doc).  
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Document S1 
 
Document S1. CancerGD short tutorial (20 mins) 
 
Overview: 
 
CancerGD.org provides a search interface for genetic dependencies identified 
in loss-of-function screens in panels of tumor cell lines. A genetic dependency 
is identified when there is a statistical association between the presence of a 
particular mutation and increased sensitivity to the inhibition of a specific 
gene. These dependencies are identified by integrating large-scale loss-of-
function screens in panels of cell lines with genotype data for the same cell 
lines. In CancerGD we store all nominally significant dependencies (P < 0.05) 
with a common language effect size > 65% (see 
http://www.cancergd.org/faq/#effectsize for an explanation). A goal of this 
resource is to help understand genetic dependencies in the context of known 
functional interaction networks (e.g. protein-protein interactions). Towards this 
end we have developed simple functionality to identify those genetic 
dependencies that occur within pathways (i.e. where the driver gene and the 
target dependency belong to the same pathway) and between pathways (i.e. 
where the dependencies associated with a given driver gene belong to the 
same complex or pathway as each other).  To further facilitate follow on 
studies we have also annotated all dependencies in the database according 
to the availability of inhibitors for the target genes. 
 
Here we provide a simple tutorial that takes the user through the main 
functionality of www.cancergd.org. We show how CancerGD can be used to 
browse and analyse the dependencies associated with ERBB2 amplification 
in the Campbell et al paper published in Cell Reports (2016). This tutorial 
should take approximately 20 minutes to complete. 
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Step 1 – retrieving the dependencies associated with a driver gene 
 
Navigate to http://www.cancergd.org/ in your internet browser. You will see a 
search box resembling the below image. In the Driver gene field type 
‘ERBB2’, in the Tissue type dropdown select ‘Pan cancer’ and in the Study 
dropdown please select ‘Campbell(2016)’.  Click the Search button 
 
 
 
You will be presented with a table of results resembling the below image. The 
top of the page provides details (gene synonyms, a gene description, links to 
the gene on external resources) for the selected driver gene (ERBB2). The 
bottom of the page is a table displaying all of the nominally significant 
dependencies associated with the selected driver gene (ERBB2) in the 
selected tissue (pan-cancer, i.e. across all tissue types) from the selected 
study (Campbell et al).   
 
 
 
Clicking on any gene name in the ‘Dependency’ column will present the user 
with a view of the evidence supporting that dependency. Click on MAP2K3 to 
proceed to the next step 
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Step 2 – viewing the data supporting individual dependencies 
 
You will be presented with a window resembling the below image. This view 
presents the data supporting the association between ERBB2 amplification 
and sensitivity to RNAi reagents targeting MAP2K3. 
 
 
 
This is an interactive box plot (http://www.cancergd.org/faq/#boxplots) that 
displays the sensitivity of cell lines partitioned according to ERBB2 status to 
RNAi reagents targeting MAP2K3. The cell lines featuring an alteration of 
ERBB2 are displayed on the right and the cell lines without the alteration are 
on the left. Each colored shape represents a cell line and the position along 
the y-axis indicates how sensitive that cell line is to the RNAi reagents 
targeting the gene indicated (MAP2K3). A lower position on the y-axis 
indicates greater sensitivity. The colors indicate the tissue of origin for each 
cell line, as indicated in the legend on the right hand side. Toggles in the 
legend facilitated hiding or displaying cell lines from specific histologies. To 
see how the dependency between ERBB2 and MAP2K3 appears when breast 
cell lines are removed uncheck the box beside ‘Breast’ in the legend.  
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To download a high-resolution copy of this image click ‘Download boxplot as 
PNG image’. To download the raw data supporting this dependency in a 
comma separated text file, click ‘Download boxplot as CSV file’. This can be 
opened with Microsoft Excel or similar applications.  
 
To see the details associated with a specific cell line hover your cursor over 
the shape corresponding to that cell line (e.g. above we hover over the cell 
line with the greatest sensitivity to MAP2K3 inhibition). 
 
Click the X in the top right to close this image and return to the table that lists 
genetic dependencies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 30	
 
Step 3 – filtering dependencies with a known functional relationship to 
the driver gene 
 
One of the goals of this resource is to facilitate the interpretation of genetic 
dependencies and to develop filters to prioritize promising candidates for 
follow up studies. The simplest approach is to focus on dependencies that 
have a known relationship (e.g. a protein-protein interaction) with the driver 
gene. To identify these - choose 'Any' in the 'String Interaction' column. This 
will filter the table to show only the genetic dependencies that have a 
functional relationship (e.g. protein-protein interaction) with ERBB2 as 
displayed below. 
 
 
 
This identifies the ERBB2 downstream effector PIK3CA and the ERBB2 
binding partner ERBB3 among others. These functional relationships are 
obtained from the STRING database (http://string-db.org/). Clicking on text 
inside the String Interaction column (e.g. Highest) will bring the user to the 
STRING database where the data supporting the functional interaction 
between the driver gene and the dependency will be displayed.  
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Step 4 – identifying interactions between the dependencies associated 
with a driver gene 
 
An alternative to identifying the known functional interactions between a driver 
gene and its dependencies is to try to understand the relationship between all 
of the dependencies associated with a given driver gene. In this way it may be 
possible to identify pathways or protein complexes that the driver gene is 
associated with an increased dependency upon. For this analysis we again 
rely on the STRING database (http://string-db.org/). To view all of the 
interactions between the dependencies associated ERBB2 click on 
the 'Stringdb Image' button above the dependencies table.  
 
 
 
 
This will take a moment to retrieve an image similar to that below showing 
high-confidence functional interactions between the genes identified 
as ERBB2 dependencies. You can see that ERBB2 amplification is 
associated with an increased dependency upon a group of kinases 
functionally related to ERBB2 and PI3K signaling, as well as a group of genes 
involved in map kinase signaling.  
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By selecting ‘Stringdb Interactive’ instead of ‘Stringdb image’ you can view 
an interactive version of this network on the STRING website. This will allow 
you to view the evidence supporting each functional interactions, to alter the 
layout of the network, and to filter the network in different ways. Click the X in 
the top right of the Stringdb image to close the image and return to the table 
listing dependencies. 
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Step 5 – identifying dependencies that can be exploited with existing 
inhibitors 
 
A further goal of CancerGD is to facilitate follow on experimentation. One 
means to further explore or validate a dependency is to see if the same effect 
is observed using small molecule inhibitors rather than RNAi reagents. To that 
end we annotate all of our dependencies according to the availability of 
inhibitors. To view genes with available inhibitors, select ‘Any’ in the 
‘Inhibitors’ column toggle. You will see a view resembling the below.  
 
 
 
This filters the dependencies so that only those genes with known inhibitors 
are presented. The mapping from genes to inhibitors is taken from the DGIdb 
resource (http://dgidb.genome.wustl.edu/). Clicking on any inhibitor name in 
the Inhibitors column will bring the user to DGIdb, where details on the 
inhibitor are provided. For some genes there are more inhibitors available 
than can be presented in the Inhibitors column. These are indicated with the 
text [more]. Clicking on [more] in any entry in the Inhibitors column will display 
the full list of inhibitors associated with that gene in a window like that shown 
below : 
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Clicking any inhibitor name within this window will bring the user to DGIdb, 
where details on the inhibitor are provided. Click the X to close this window. 
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Step 6 – identifying dependencies that have been observed in multiple 
datasets 
 
A dependency observed in any one screen may be a statistical artefact, a 
context specific dependency, or a false positive resulting from the off-target 
effects of gene targetting reagents. Those dependencies observed in multiple 
independent datasets may make more promising candidates as they are less 
likely to be artefacts or false positive effects. To prioritise these for further 
validation, CancerGD allows easy filtering of the dependencies observed 
independently in multiple datasets. To view dependencies that have been 
associated with the same driver gene in the same tissue type, select ‘Yes’ in 
the ‘Multiple Hit’ column toggle. You will see a view resembling the below.  
 
 
 
Hover over the ‘Yes’ text in the “Multiple Hit” column to see the details of the 
screens that a specific gene has been identified as a dependency in. 
 
Conclusion 
 
You have now completed a tour of the main www.cancergd.org functionality. 
Further information is available on the FAQ (http://www.cancergd.org/faq/)  
page. We welcome feedback through the contact page 
(http://www.cancergd.org/contact/). 
 
